electroCore Boosts Revenue 28% on VA Growth and Quell Adoption
Event summary
- Q2 2026 revenue rose 28% YoY to $9.5M, driven by VA prescription sales and Quell product adoption.
- Net loss narrowed 17% YoY to $3.1M, with Adjusted EBITDA loss improving 26%.
- Quell revenue surged ~700% YoY to $1.3M, with $3.8M sold into the VA since acquisition.
- Company restructured commercial organization, doubling sales regions and hiring new reps.
- Raised full-year 2026 revenue guidance to >30% growth and targets positive Adjusted EBITDA by Q3 2027.
The big picture
electroCore's Q2 results highlight its strategic pivot toward government channels and bioelectronic product diversification. The company's restructuring aims to improve operational efficiency amid rising media costs, positioning it for long-term scalability in federal markets. With $10M in cash reserves as of June 30, 2026, electroCore faces execution risks but shows early signs of sustainable growth.
What we're watching
- VA Market Penetration
- Whether electroCore can sustain its growth in the VA channel, where it has achieved ~2.7% penetration of the headache market.
- Cost Efficiency
- The pace at which restructuring efforts reduce sales and marketing expenses as a percentage of revenue.
- Quell Scalability
- How electroCore will leverage the Quell product line beyond the VA, particularly in commercial health systems like Kaiser Permanente.
Related topics